Earned Wealth Advisors LLC Boosts Position in Eli Lilly and Company $LLY

Earned Wealth Advisors LLC raised its position in Eli Lilly and Company (NYSE:LLY) by 21.9% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,746 shares of the company’s stock after acquiring an additional 494 shares during the quarter. Earned Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $2,095,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Vanguard Group Inc. increased its holdings in Eli Lilly and Company by 1.5% during the second quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock valued at $62,680,004,000 after buying an additional 1,183,038 shares during the last quarter. Laurel Wealth Advisors LLC grew its position in shares of Eli Lilly and Company by 78,621.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after acquiring an additional 11,537,661 shares during the period. Norges Bank purchased a new stake in shares of Eli Lilly and Company in the 2nd quarter worth $8,827,714,000. Jennison Associates LLC raised its holdings in Eli Lilly and Company by 4.3% in the 2nd quarter. Jennison Associates LLC now owns 5,447,636 shares of the company’s stock worth $4,246,596,000 after purchasing an additional 226,620 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in Eli Lilly and Company by 2.0% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 5,359,653 shares of the company’s stock worth $4,178,010,000 after purchasing an additional 103,119 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $1,041.78 on Tuesday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,111.99. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The firm’s fifty day moving average is $1,017.48 and its 200 day moving average is $853.10. The company has a market cap of $984.88 billion, a price-to-earnings ratio of 50.97, a PEG ratio of 0.78 and a beta of 0.35.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company’s revenue for the quarter was up 53.9% on a year-over-year basis. During the same period last year, the company earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a $1.73 dividend. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s payout ratio is currently 29.35%.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Morgan Stanley raised their price objective on Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the stock an “overweight” rating in a research note on Monday, November 24th. Scotiabank began coverage on shares of Eli Lilly and Company in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $1,165.00 target price on the stock. The Goldman Sachs Group lifted their price target on shares of Eli Lilly and Company from $951.00 to $1,145.00 and gave the company a “buy” rating in a report on Monday, December 15th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Finally, Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Five equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $1,161.27.

Key Stores Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Analysts and commentary cite Lilly’s long‑term growth setup — strong GLP‑1 franchise, a deep obesity pipeline and AI/innovation tailwinds — that support multi‑year revenue upside and justify bullish ratings. 3 Reasons Why Lilly (LLY) Is a Great Growth Stock
• Positive Sentiment: Several investment writeups highlight Lilly as a top stock for 2026 and note the company’s recent revenue trajectory and guidance, which support longer‑term earnings expectations. 3 Top Ranked Stocks to Buy for 2026 (LLY, WFRD, PGY)
• Neutral Sentiment: Market pieces debate whether now is a buy, hold or sell after a sharp 3‑month gain; these narratives can increase short‑term volatility but don’t change fundamentals immediately. LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock?
• Neutral Sentiment: Sector/idea pieces list Lilly among AI‑enabled medtech/biotech names to watch — a thematic positive over time but unlikely to drive intraday moves. Watch 5 AI-Powered Medical Stocks for a Strong Portfolio in 2026
• Negative Sentiment: Market reaction to Novo Nordisk’s U.S. launch of an oral Wegovy pill is the headline pressure point — investors are pricing in faster share loss and margin competition in the obesity/weight‑loss market. Novo Nordisk Stock Jumps as it Battles Eli Lilly for Market Share with $149 Wegovy Pill Launch
• Negative Sentiment: Legal and political risk intensified as Indiana’s Attorney General filed a lawsuit against Lilly over insulin pricing — this raises potential headline/legal costs and regulatory scrutiny. Indiana sues Eli Lilly over insulin prices
• Negative Sentiment: Short‑term selling pressure is also reflected in quick market checks and opinion pieces suggesting profit‑taking or repositioning after Lilly’s strong run and rising valuation multiples. Eli Lilly Stock (LLY) Falls 4% as Rival Novo Nordisk Begins Selling Obesity Pill in U.S.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.